As shown in Table 1, over 95% of NPC cases (titer 1 : 10 to 1 : 640) and 42%–45% of the controls (titer 1 : 10 to 1 : 160) were positive for EBV/IgA/VCA antibodies; about 60%–72% of NPC cases (titer 1 : 5 to 1 : 640) and 2%-3% of the controls (titer 1 : 5 to 1 : 80) were positive for EBV/IgA/EA antibodies in the two cohorts. The gene discussed is CD79A; the disease is nasopharyngeal carcinoma.